|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Eurofins enhances clinical and COVID-19 testing offering in Japan through acquisition of Genetic Lab Co.,Ltd. |
 |
|
Eurofins Scientific (EUFI.PA), the global scientific leader in bioanalytical testing and a leader in clinical diagnostics testing, announces a share purchase agreement with Transgenic Inc. (2342:JP, Tokyo stock exchange) to acquire Genetic Lab Co.,Ltd. (“G Lab”), a molecular biology based testing provider for diagnostics, biomarker development and drug discovery. The acquisition will further enhance Eurofins’ expansion in Asia and complement its global network of clinical diagnostics laboratories focused on specialised and advanced genetic testing.
G Lab employs over 70 staff and generated revenues of over EUR 13m in the financial year ending March 2021. Initially established as a genetics technology based bio venture in 2000, G Lab has developed a reputation among clinical communities in Japan for the CAP accredited quality services provided by its technical experts, in-house medical pathologists and cytotechnologists. G Lab also provides diversified testing services supporting biomarker development for companion drugs. Since Mar 2020, G Lab has played an important role in the COVID-19 response in Japan, by facilitating PCR testing, and supporting Hokkaido prefecture and Sapporo city with their COVID-19 testing programmes.
Through this acquisition, the Eurofins network will further strengthen its position in the Japanese market, where it is currently the market leader in environment testing and non-invasive prenatal testing, by extending its service offering in BioPharma services and clinical testing in Japan, notably increasing its COVID-19 testing product and service offering to support the fight against the pandemic.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Watson-Marlow Fluid Technology Solutions and the National Institute for Bioprocessing Research and Training Partner for Biopharma Training Programme
Falmouth, UK, 3rd May 2022 / Sciad Newswire / Watson-Marlow Fluid
Technology Solutions (WMFTS) today announces it has partnered with the
National Institute of Bioprocessing Research and Training (NIBRT) to
develop and deliver a combined in-person and online global biopharma
training programme for employees.
More info >> |
|
 |
White Papers |
 |
|
High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts
ILC Dover
As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >> |
|
 |
Industry Events |
 |
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022)
20-21 June 2022, Berlin, Germany
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) is
held on June, 20-21, 2022 in Berlin, Germany. The Congress gathers
pharmaceutical companies, CMOs and CDMOs, governmental bodies together
with pharmaceutical equipment providers and service companies to discuss
the manufacturing and packaging processes of the pharmaceutical
industry. Among the participating companies are Bayer, Sandoz, Merck,
Novartis, Roche, Genveon, Samsung Biologics, Pfizer.
More info >> |
|
|
